NASDAQ : UPB
Upstream Bio, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.27 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 179.10M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 186.77M |
| Enterprise Value | -73.58M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 54.77M |
| Shares Outstanding | 54.77M |
| Shares Change (YoY) | +38.95% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 75.95% |
| Float | 42.81M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 59.14 |
| Forward PS | 124.30 |
| PB Ratio | 0.69 |
| P/TBV Ratio | 0.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 27.99 |
| Quick Ratio | 26.38 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -46.05% |
| Return on Assets (ROA) | -30.28% |
| Return on Invested Capital (ROIC) | -31.15% |
| Return on Capital Employed (ROCE) | -62.68% |
| Weighted Average Cost of Capital (WACC) | 11.83% |
| Revenue Per Employee | $42,107 |
| Profits Per Employee | -$2.09M |
| Employee Count | 75 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.39 |
| 52-Week Price Change | -85.90% |
| 50-Day Moving Average | 4.93 |
| 200-Day Moving Average | 9.27 |
| Relative Strength Index (RSI) | 40.64 |
| Average Volume (20 Days) | 1,320,594 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.48M |
| Short Previous Month | 4.51M |
| Short % of Shares Out | 8.18% |
| Short % of Float | 10.47% |
| Short Ratio (days to cover) | 5.02 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 3.16M |
| Gross Profit | 3.16M |
| Operating Income | -169.98M |
| Pretax Income | -156.50M |
| Net Income | -156.50M |
| EBITDA | -169.78M |
| EBIT | -169.98M |
| Loss Per Share | -$2.89 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 261.31M |
| Total Debt | 954,000 |
| Net Cash | 260.35M |
| Net Cash Per Share | $4.75 |
| Equity (Book Value) | 270.96M |
| Book Value Per Share | 4.95 |
| Working Capital | 269.61M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -136.34M |
| Capital Expenditures | -118,000 |
| Depreciation & Amortization | 202,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -136.46M |
| FCF Per Share | -$2.49 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -5,382.65% |
| Pretax Margin | -4,955.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -38.95% |
| Shareholder Yield | -38.95% |
| Earnings Yield | -84.63% |
| FCF Yield | -73.06% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $29.83 |
| Price Target Difference | 774.78% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | -25.80% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 50.27 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |